-
Product Insights
Vertigo Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Vertigo - Global Clinical Trials Review, 2025" provides an overview of Vertigo Clinical trials scenario. This report provides top line data relating to the clinical trials on Vertigo. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
Obsessive-Compulsive Disorder Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Obsessive-Compulsive Disorder - Global Clinical Trials Review, 2025" provides an overview of Obsessive-Compulsive Disorder Clinical trials scenario. This report provides top line data relating to the clinical trials on Obsessive-Compulsive Disorder. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Kidney Disease (Nephropathy) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Kidney Disease (Nephropathy) - Global Clinical Trials Review, 2025" provides an overview of Kidney Disease (Nephropathy) Clinical trials scenario. This report provides top line data relating to the clinical trials on Kidney Disease (Nephropathy). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Product Insights
Hypoglycemia Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Hypoglycemia - Global Clinical Trials Review, 2025" provides an overview of Hypoglycemia Clinical trials scenario. This report provides top line data relating to the clinical trials on Hypoglycemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
Alopecia Universalis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Alopecia Universalis - Global Clinical Trials Review, 2025" provides an overview of Alopecia Universalis Clinical trials scenario. This report provides top line data relating to the clinical trials on Alopecia Universalis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Sector Analysis
Mucopolysaccharidosis I (MPS I) (Hurler syndrome) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Mucopolysaccharidosis I (Hurler syndrome) Therapeutics. - In 2024, there were more than 1,740 diagnosed prevalent cases of MPS I in the 16 countries covered in GlobalData’s epidemiology forecast. - Currently, only one FDA-approved innovator drug is available for the treatment of MPS I. - The MPS I pipeline holds 16 molecules, with only one molecule present in Phase III development. - Over the past 10 years,...
-
Thematic Analysis
Healthcare M&A Deals Q1 2025 - Top Themes: Strategic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in Q1 2025 in the Healthcare Sector.
-
Sector Analysis
Non-small Cell Lung Cancer (NSCLC) in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033
Report Value Proposition – Why This Matters for You The Non-Small Cell Lung Cancer (NSCLC) therapeutics market across the seven major markets (7MM) was valued at $24.1 billion in 2022 and is forecast to reach $56.5 billion by 2032, reflecting a CAGR of 8.9% during the forecast period. This report helps stakeholders understand how advances in immunotherapy, targeted therapies, precision medicine, and pipeline innovation are transforming the treatment landscape for NSCLC. It provides comprehensive analysis of disease epidemiology, patient populations,...
-
Sector Analysis
Dermatomyositis (DM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Dermatomyositis Therapeutics. - GlobalData epidemiologists estimate that there were 791,779 diagnosed prevalent cases of Dermatomyositis (DM) in 2024, which is expected to increase slightly to 848,500 diagnosed prevalent cases by 2029. - Currently, the DM market is saturated with generic drugs, and the glucocorticoid receptor agonist drug class dominates the approved innovator drugs - The DM pipeline holds 39 molecules, with no assets in the pre-registration...
-
Thematic Analysis
T-Cell Immunotherapy Landscape - Comprehensive Analysis of Current Drugs and Dynamics
This report investigates the impacts and development of T-Cell Immunotherapies within the pharmaceutical industry from the standpoint of drug development. It provides a high-level analysis of key trends and movements within the industry via regulatory, clinical, and market-based analysis, allowing you to discern the large-scale changes within the market and how best to pivot to prioritize future changes in the market.
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.